ZIOPHARM Oncology Inc. (ZIOP)

5.61
0.16 2.90
NASDAQ : Health Technology
Prev Close 5.45
Open 5.47
Day Low/High 5.47 / 5.77
52 Wk Low/High 1.56 / 6.30
Volume 722.78K
Avg Volume 1.73M
Exchange NASDAQ
Shares Outstanding 162.39M
Market Cap 959.75M
EPS -0.50
P/E Ratio 5.74
Div & Yield N.A. (N.A)

Latest News

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...

The Good, the Bad and the Ugly (Mid-Afternoon Edition)

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...

Takeaways And Observations

For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...

Takeaways & Observations

Risk happens fast.  Most don't short and shouldn't short -- it's a game that requires volumes of risk control.  However, I would continue to maintain well above-average cash positions.  Today was not a benign event, in my view.  Nor was it likely a ...

Don't Overlook Ziopharm Oncology

Don't Overlook Ziopharm Oncology

The stock is poised for an upside breakout.

Takeaways & Observations

I wanted to start by congratulating El Capitan for his 12th anniversary for Mad Money tonight. Like the Energizer Bunny, he keeps going and going...  HIgh yield gets junky -- despite protestations from Merrill's junk department! I have been warning ...

My Takeaways and Observatons

"As to the markets, it trades like participants are sleeping off hangovers from partying hard during last night's Super Bowl thriller." -- "Is Another Lesson Soon to be Learned?"   With such little price action it seemed like a snore fest (see above...

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

My Takeaways and Observations

"Well, they call you lady luck But there is room for doubt At times you have a very un-lady-like way Of running out..." -- Guys and Dolls, Luck Be A Lady (Frank Sinatra)  Trump will not likely Make Twitter Great Again.   I, bear.    Explaining my pr...

My Takeaways and Observations

Donald Trump may make illiquidity, volatility and uncertainty great again.    More "Penneys" from heaven, an analysis of the company's quarterly release.    Trade of the Week -- short Apple . Here and here.    I sold my retail long rentals for sick ...

Bullish and Bearish Chart Reversals

Bullish and Bearish Chart Reversals

What stocks have changed direction in the past week.

My Takeaways and Observations

My fellow Americans and Real Money Pro subscribers: Politics will weigh on the markets during the months leading up to the election.  What, me, worry? Bank of America reports there is more than $13 trillion in negative-yielding sovereign debt now. T...

Build a Core Position in Biotech Intrexon at These Lower Prices

Following a 40% decline, now looks good for scaling into the stock.

Market Bounce Lands With a Thud

Profit-taking results in a weak close.

Market's Not in the Mood to Move

Attention turns to earnings and away from Greece, Fed.

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

When to take profits is a tricky but important decision.

A Steady but Sloppy Day

Awaiting Yellen, but some churn wouldn't hurt.

The Trend Is Up

Fighting this market isn't a money maker.

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Fibrocell Science and Prothena have several 'shots on goal.'

Where's the Worry?

It may not feel intuitive to embrace this market, but it works.

Two Attractive Biotech Plays

Two Attractive Biotech Plays

Speculative growth investors might want to test the water.

Home Prices Spark Rally

Home Prices Spark Rally

Higher home prices rallies stock investors, while Ziopharm does not cure cancer and Buffett picks up goldman stock - details from TheStreet's Debra Borchardt.

The Next Big Thing In Biotech: Decision Week

The Next Big Thing In Biotech: Decision Week

Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.